Latest news
Inetetamab-Pyrotinib Regimen Shows High pCR in HER2-Positive Breast Cancer - Targeted OncologyTargeted Oncology · Sat, 08 Aug 2026 15:11:40 GMTAstraZeneca Pharma Gets CDSCO Nod To Sell Enhertu For Breast Cancer - NDTV ProfitNDTV Profit · Sat, 08 Aug 2026 09:00:27 GMTAMH Levels May Predict Adjuvant Chemotherapy Benefit in Premenopausal Women With Breast Cancer - The ASCO PostThe ASCO Post · Fri, 07 Aug 2026 15:35:11 GMTHow to Ask for Help if You Have HR+/HER2- Metastatic Breast Cancer - Everyday HealthEveryday Health · Fri, 07 Aug 2026 15:28:29 GMTTrastuzumab Rezetecan Improves Progression-Free Survival in HER2-Positive Metastatic Breast Cancer - The ASCO PostThe ASCO Post · Fri, 07 Aug 2026 14:42:22 GMTHR-Positive Breast Cancer: ctDNA-Guided De-escalation and Clinical Uncertainty - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Fri, 07 Aug 2026 12:25:58 GMTHR-Positive Breast Cancer: Differentiating Oral SERDs and Real-World Decision-Making - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Fri, 07 Aug 2026 12:25:40 GMTHER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer - The ASCO PostThe ASCO Post · Thu, 06 Aug 2026 13:47:28 GMT